Last reviewed · How we verify
pharmacogenetic algorithm
At a glance
| Generic name | pharmacogenetic algorithm |
|---|---|
| Sponsor | University of Pernambuco |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Protocol for Improvement of Therapy With Warfarin (PHASE3)
- DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients (PHASE2)
- Warfarin Anticoagulation in Patients in Sub-Saharan Africa
- Dexmedetomidine for Analgosedation to Newborn Infants During Neonatal Intensive Care
- A Genomic Approach for Clopidogrel in Caribbean Hispanics (EARLY_PHASE1)
- Clonidine for Analgesia to Preterm Infants During Neonatal Intensive Care
- A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
- Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pharmacogenetic algorithm CI brief — competitive landscape report
- pharmacogenetic algorithm updates RSS · CI watch RSS
- University of Pernambuco portfolio CI